Liminatus Pharma Inc. Class A (LIMN)
NASDAQ: LIMNHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
LIMN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $4.96M
- EPS (TTM)
- -$23.50
- Dividend yield
- None
- 52-week range
- 3.29 – 141.50
- Day range
- 3.53 – 3.95
- Volume / Avg
- 38.56K / 453.28K
- Beta
- —
- Shares outstanding
- 1.34M
52-week range
LIMN stock today
Liminatus Pharma (LIMN) closed at $3.69 on Oct 8, down 4.65% (-$0.18), versus the S&P 500's 0.47% decline. Trading was light, with 38.56K shares changing hands, about 9% of the average daily volume. At this level, LIMN sits near the bottom of its 52-week range of $3.29 to $141.50: 97.4% below the high and 12.2% above the low.
Liminatus Pharma has posted a net loss over the last twelve months (EPS of -$23.50), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Liminatus Pharma
Company profileLiminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Chris Kim J.D., L.L.M.
- Headquarters
- Cerritos, CA
- Employees
- 1
- Website
- liminatuspharma.com
Liminatus Pharma peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PMCBPharmaCyte Biotech Inc. | 0.3974 | -2.02% | $4.27M | vs LIMN |
| CLDICalidi Biotherapeutics Inc. | 1.04 | +2.97% | $3.82M | vs LIMN |
| SLXNSilexion Therapeutics Corp | 0.2349 | -7.37% | $3.40M | vs LIMN |
| CELZCreative Medical Technology Holdings Inc. | 0.8604 | -2.45% | $6.53M | vs LIMN |
| BTTCBlack Titan Corporation | 0.495 | -3.51% | $6.78M | vs LIMN |
| VIVSVivoSim Labs Inc. | 0.1772 | -7.47% | $2.94M | vs LIMN |
| AIMAIM ImmunoTech Inc. | 0.1796 | -1.75% | $7.17M | vs LIMN |
| HLSQTessera Defense and Homeland Security Inc. | 0.2915 | -5.72% | $2.63M | vs LIMN |
Indexes, lists and sector
Liminatus Pharma stock FAQ
What is Liminatus Pharma's stock price today?
LIMN last traded at $3.69 as of Oct 8, 4:00 PM EDT, down 4.65% on the day. Prices are delayed at least 15 minutes.
Who is Liminatus Pharma's CEO?
Mr. Chris Kim J.D., L.L.M. is the chief executive officer of Liminatus Pharma Inc. Class A, which has about 1 employees.
What is the LIMN 52-week high?
The 52-week high for LIMN is $141.50 and the 52-week low is $3.29. The stock is currently 97.4% below its high.